Core Laboratories N.V. (NYSE:CLB) has been assigned a $97.00 target price by Piper Jaffray Companies in a research report issued on Monday. The firm presently has a “hold” rating on the oil and gas company’s stock. Piper Jaffray Companies’ target price indicates a potential upside of 3.39% from the company’s previous close.

A number of other brokerages have also recently issued reports on CLB. Zacks Investment Research cut shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. ValuEngine raised shares of Core Laboratories N.V. from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Citigroup Inc. lowered their price target on shares of Core Laboratories N.V. from $102.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, July 26th. Royal Bank Of Canada reissued a “buy” rating and set a $115.00 price target on shares of Core Laboratories N.V. in a research report on Friday, September 1st. Finally, Cowen and Company reissued a “hold” rating and set a $100.00 price target on shares of Core Laboratories N.V. in a research report on Friday, September 1st. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $110.91.

Core Laboratories N.V. (NYSE CLB) traded up 6.92% during midday trading on Monday, hitting $93.82. 1,188,043 shares of the company were exchanged. Core Laboratories N.V. has a 1-year low of $86.55 and a 1-year high of $125.83. The stock has a 50 day moving average of $94.90 and a 200 day moving average of $101.06. The firm has a market capitalization of $4.14 billion, a PE ratio of 57.56 and a beta of 1.63.

Core Laboratories N.V. (NYSE:CLB) last issued its quarterly earnings results on Monday, October 23rd. The oil and gas company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.04. Core Laboratories N.V. had a net margin of 11.80% and a return on equity of 49.29%. The company had revenue of $166.20 million during the quarter, compared to analysts’ expectations of $160.94 million. During the same period last year, the company posted $0.38 EPS. Core Laboratories N.V.’s revenue was up 1.4% on a year-over-year basis. On average, equities analysts predict that Core Laboratories N.V. will post $1.96 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/24/piper-jaffray-companies-reiterates-97-00-price-target-for-core-laboratories-n-v-clb.html.

Institutional investors have recently modified their holdings of the business. Parallel Advisors LLC raised its holdings in Core Laboratories N.V. by 13.1% in the second quarter. Parallel Advisors LLC now owns 1,008 shares of the oil and gas company’s stock worth $101,000 after buying an additional 117 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Core Laboratories N.V. by 63.7% during the second quarter. The Manufacturers Life Insurance Company now owns 1,128 shares of the oil and gas company’s stock valued at $114,000 after purchasing an additional 439 shares during the last quarter. Shine Investment Advisory Services Inc. purchased a new position in shares of Core Laboratories N.V. during the second quarter valued at approximately $134,000. Advisory Services Network LLC raised its holdings in shares of Core Laboratories N.V. by 33.3% during the second quarter. Advisory Services Network LLC now owns 1,365 shares of the oil and gas company’s stock valued at $138,000 after purchasing an additional 341 shares during the last quarter. Finally, First Bank & Trust raised its holdings in shares of Core Laboratories N.V. by 5.8% during the second quarter. First Bank & Trust now owns 1,493 shares of the oil and gas company’s stock valued at $152,000 after purchasing an additional 82 shares during the last quarter.

Core Laboratories N.V. Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Analyst Recommendations for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.